S. 2665
Referred to CommitteeA bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
4/12/2018 • Senate
Summary
This bill requires the Food and Drug Administration (FDA) to develop guidance regarding how it will assess evidence to support claims of opioid sparing (i.e., the use of drugs that reduce pain while also allowing reduced use or avoidance of oral opioids) for non-opioid or other non-addictive medical products intended to treat pain.
The FDA must also develop guidance regarding how it will consider the misuse and abuse of drugs in making certain determinations of safety.
Introduced in Senate • 4/12/2018
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (2)
Party Breakdown
Sponsor
Cosponsors (1)
Bill Journey
Originated in the Senate
Introduced
April 12, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law